Delivery Order SPE2DB25D9320-SPE2DB25FWFAJ
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $7,955.39 by the Defense Logistics Agency on July 23, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This firm fixed-price delivery order, with an ultimate completion date of July 24, 2025, was issued without a set-aside designation, allowing the vendor to compete on an unrestricted basis. The award represents a continuation...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This delivery order was issued without a set-aside designation and is scheduled for completion by July 22, 2025, with performance taking place at the contractor's Park Ridge facility. The award represents a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency on July 14, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This firm fixed-price delivery order, which is expected to be completed by July 15, 2025, represents a discrete fulfillment under the company's larger Indefinite Delivery Contract with DLA. The award carries no set-aside...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $25,017.54 by the Defense Logistics Agency on June 18, 2025, for the supply of Xtandi 40 mg tablets (120-count units). The award utilizes a firm fixed-price contract structure with no set-aside designation, and is scheduled for ultimate completion by June 20, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency on July 16, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract employs firm fixed-price pricing and carries an ultimate completion date of July 17, 2025. This delivery order was awarded without a set-aside designation, allowing the vendor to compete directly in the federal...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency (DLA) on August 25, 2025, for the supply of Xtandi 80 mg tablets (60-count packages). The award carries a firm fixed-price structure with an ultimate completion date of August 26, 2025. This delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete on an...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 3, 2025, for the supply of Xtandi 80 mg tablets (60-count units) with a ceiling value of $4,169.59. This delivery order, which carries no set-aside designation, is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a $4,169.59 firm fixed-price delivery order from the Defense Logistics Agency on April 29, 2025, for 60 tablets of Xtandi 80 mg. This award represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at approximately $500 million and valid through November 2026. The contract carries no set-aside...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,565.70 for Xtandi 40mg capsules (120 count) by the Defense Logistics Agency's Medical Supply Chain on September 13, 2025. This firm fixed-price delivery order carries no set-aside designation and is being performed at the awardee's Park Ridge location. The award represents a single delivery order under DMS Pharmaceutical Group's larger...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $17,245.40 by the Defense Logistics Agency on August 13, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The award carries no set-aside designation and is structured as a firm fixed-price delivery order with an ultimate completion date of August 14, 2025. This award is issued under DMS Pharmaceutical Group's larger...
- SPE2DB25D9320Indefinite Delivery Contract
- SPE2DB25D9320-SPE2DB25FWFAJDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency on April 23, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This firm fixed-price delivery order, which is scheduled for completion by April 24, 2025, was issued without a set-aside designation. The award represents a continuation of DMS Pharmaceutical Group's substantial role as a critical supplier within the federal pharmaceutical supply chain, leveraging its position as a contractor under the Defense Logistics Agency's broader pharmaceutical procurement framework. This delivery order is issued under DMS Pharmaceutical Group's significant Indefinite Delivery Contract with the Defense Logistics Agency, valued at $499,999,999 and valid through November 2026. The parent contract enables the agency to procure a comprehensive portfolio of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare facilities worldwide. Xtandi, an oncology treatment, exemplifies the specialized pharmaceutical products within the contract's scope that serve military health system requirements across multiple therapeutic categories and delivery formats.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 4/23/25 |